Recurrent Inflammatory Flares in HIV-Infected Patients: Consider Castleman Disease!

Background. Transient inflammatory flares are common in clinical care of human immunodeficiency virus (HIV)–infected patients. In-depth investigations are not performed routinely because patients often recover without therapeutic interventions, and therefore, the etiologies of these inflammatory flares frequently remain unknown. Case. We report a case of an HIV-infected patient with recurrent inflammatory flares during several years in whom diagnostic workup with a lymph node biopsy finally revealed multicentric Castleman disease (MCD). The patient was treated with etoposide and rituximab until November 2013 and achieved ongoing complete clinical remission. Conclusion. Recent effective therapeutic regimens offer an opportunity to prevent serious complications of MCD including its malignant transformation, provided that the diagnosis is established early enough. Therefore, clinicians should consider MCD in the differential diagnosis of self-limiting inflammatory flares, especially in HIV-infected patients.

[1]  É. Oksenhendler,et al.  Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. , 2012, Blood.

[2]  B. Barlogie,et al.  Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. , 2010, Clinical advances in hematology & oncology : H&O.

[3]  É. Oksenhendler.  HIV-associated multicentric Castleman disease , 2009, Current opinion in HIV and AIDS.

[4]  S. Montoto,et al.  Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease , 2007, Annals of Internal Medicine.

[5]  É. Oksenhendler,et al.  Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Casper,et al.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care , 2005, British journal of haematology.

[7]  C. Boshoff,et al.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. , 2000, Blood.

[8]  B. Castleman,et al.  Hyaline‐vascular and plasma‐cell types of giant lymph node hyperplasia of the mediastinum and other locations , 1972 .

[9]  A. Dispenzieri.  Castleman disease. , 2008, Cancer treatment and research.

[10]  M. Du,et al.  Fatal HHV-8-associated hemophagocytic syndrome in an HIV-negative immunocompetent patient with plasmablastic variant of multicentric Castleman disease (plasmablastic microlymphoma). , 2006, The American journal of surgical pathology.